3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Urinary Bladder Neoplasms
3
Neoplasm Metastasis
2
Thymoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Melanoma
1
Lymphatic Metastasis
1
Head and Neck Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 10
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
Cisplatin
4
Radiotherapy
3
Cetuximab
3
pembrolizumab
2
Surveys and Questionnaires
2
Carboplatin
2
olaparib
1
niraparib
1
fludarabine
1
dostarlimab
1
cemiplimab
1
calcipotriene
1
avelumab
1
atezolizumab
1
aldesleukin
1
Watchful Waiting
1
Tiragolumab
1
Standard of Care
1
Specimen Handling
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Image-Guided
1
Platinum
1
Phlebotomy
1
Paclitaxel
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Fluorouracil
1
Fluorodeoxyglucose F18
1
Docetaxel
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Squamous Cell
×
avelumab
×
30 days
×
Clear all
NCT03494322
2026-05-20
EACH
University College, London
Phase 2
Completed
16 enrolled